Influenza

Streaming platform ZEE5 Global Unveils a High Voltage Line-Up of 111 Titles

Retrieved on: 
Friday, May 19, 2023

streaming platform for South Asian content, today unveiled a highly anticipated, blockbuster content slate with a line-up of 111+ titles spanning multiple languages.

Key Points: 
  • streaming platform for South Asian content, today unveiled a highly anticipated, blockbuster content slate with a line-up of 111+ titles spanning multiple languages.
  • The lineup showcases ZEE5 Global's significant focus on Indian language content with titles in Tamil, Telugu, Kannada, Malayalam, Bangla, Punjabi and Marathi.
  • Ms. Nimisha Pandey, Chief Content Officer – Hindi Originals, ZEE5 said, "As ZEE5 reaches its 5-year milestone, we are creating ourselves, one story at a time.
  • Users can download the ZEE5 Global app from Google Play Store / iOS App Store on Roku devices, Apple TVs, Android TVs, Amazon Fire Stick and Samsung Smart TVs.

Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Retrieved on: 
Friday, May 19, 2023

Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay.

Key Points: 
  • Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay.
  • The Panther Fusion SARS-CoV-2/Flu A/B/RSV assay launches with the new RespDirect™ collection kit, which enables laboratories to directly load samples for processing on the Panther Fusion system without any uncapping or specimen transfer steps, saving time and reducing the potential for error, repetitive stress injuries and exposure to viruses.
  • Since the beginning of the COVID pandemic, Hologic has shipped more than 200 million SARS-CoV-2 laboratory diagnostic tests worldwide.
  • FDA clearance of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay follows the July 2022 announcement of CE marking for the same test in Europe , furthering Hologic’s position as one of the world’s largest molecular diagnostic companies.

Should I get a flu vaccine this year? Here's what you need to know

Retrieved on: 
Tuesday, May 16, 2023

So far this year, Australia has had more than 32,000 lab-confirmed cases of the flu and 32 deaths.

Key Points: 
  • So far this year, Australia has had more than 32,000 lab-confirmed cases of the flu and 32 deaths.
  • Getting a flu vaccine is the best way to protect against getting the flu.
  • Below you’ll find everything you need to know about the 2023 flu vaccine.

What are the different types of flu?

    • There are two main types of influenza: influenza A and influenza B.
    • On the surface of the influenza virus there are two main proteins, the hemagglutinin (HA or H) and neuraminidase (NA or N).
    • Different strains are named after their versions of the H and N proteins, as in H1N1 or “swine flu”.

What strains does this year’s flu shot protect against?


    Modern flu vaccines typically protect against four strains. For this year’s vaccine, the committee has recommended it includes:
    • The name is derived from the virus type (A or B)/the place it was first isolated/strain number/year isolated (virus subtype).
    • This year’s vaccine includes an influenza B isolated from Austria in 2021 (Victoria lineage) and an influenza B isolated in Phuket in 2013 (Yamagata lineage).

Who should get a flu shot?


    Health authorities recommend everyone aged six months of age or over should get the flu vaccine every year. Some groups are at greater risk of significant disease from the flu and can access the flu vaccine for free. This includes:

    Read more:
    Should I get the flu shot if I'm pregnant?

How can I get it?


    You can get a flu shot from your local general practice or pharmacy. Or you may have an opportunity to get vaccinated at your workplace if your employer supplies it. While the vaccine is free for those in the above groups, there can be a consultation or administration fee, depending on where you get your vaccine. If you aren’t eligible for a free vaccine, it usually costs around A$20-$30.

Are there different options?

    • However there is also a cell-based immunisation for people who don’t want a vaccine made in eggs.
    • When vaccines are grown in eggs, sometimes the virus can change and this might affect the level of protection.
    • The cell-based vaccine isn’t funded so patients will pay around $40 for a private prescription.

How well do they work?


    The vaccine’s effectiveness depends on how well the strains in the vaccine match those circulating. It generally reduces the chance of being admitted to hospital with influenza by 30-60%.

    Read more:
    Why can you still get influenza if you've had a flu shot?

What are the side effects?

    • When people get a flu-like illness after the vaccine, it can be due to mild effects we sometimes see after vaccination, such as headaches, tiredness or some aches and pains.
    • Alternatively, symptoms after getting a flu shot may be due to another respiratory virus such as respiratory syncytial virus (RSV) that circulates in winter.

When’s the best time to get your flu shot?


    The vaccine provides peak protection around three to four months after you get it. The peak of the flu season is usually between June and September, however this changes every year and can vary in different parts of the country. Given this, the best time to get the vaccine is usually around late April or early May. So if you haven’t already, now would be a good time to get it.

Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Monday, May 15, 2023

BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Key Points: 
  • BOTHELL, Wash., May 15, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three months ended March 31, 2023 and provides updates on its antiviral pipeline, upcoming milestones and business activities.
  • “Recent progress in advancing our pipeline of antiviral drug candidates keeps us on pace to meet our 2023 milestones,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal.
  • Research and development expenses for the first quarter of 2023 were $3.9 million, compared with $2.9 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $1.2 million, compared with $1.3 million for the first quarter of 2022.

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, May 10, 2023

Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.

Key Points: 
  • Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.
  • In the first quarter of 2023, the Company entered into a new research collaboration with a biotech company for a fully funded proof-of-concept project to express an enzyme for pharmaceutical applications.
  • G&A Expenses: General and administrative expenses for the quarter ended March 31, 2023, decreased by 10.6% to approximately $1,480,000 compared to $1,656,000 for the quarter ended March 31, 2022.
  • Other Income: Other income for the quarter ended March 31, 2023 was from the sale of the equity interest in Alphazyme, LLC.

Zhongchao Inc. Announces Naiditawei® Enrolled as a Listed Online Procurement Drug in Ten Provinces(Districts, Cities) in China

Retrieved on: 
Monday, May 8, 2023

The enrollment of Naiditawei® in the listed online procurement program is expected to alleviate the supply pressure faced by medical institutions in treating influenza A and make a positive contribution to the healthcare sector in China.

Key Points: 
  • The enrollment of Naiditawei® in the listed online procurement program is expected to alleviate the supply pressure faced by medical institutions in treating influenza A and make a positive contribution to the healthcare sector in China.
  • Naiditawei® is an anti-influenza drug introduced by Xinjiang Pharmaceutical imported from Natco Pharma Limited ("Natco") in India, commonly known as Oseltamivir Phosphate Capsules (the "Capsule").
  • Listed online procurement program is a strategic initiative that ensures transparency and fairness in drug procurement by posting drug procurement information on a specific online trading platform for drug tendering and procurement.
  • By adhering to the principle of "quality first and reasonable price," listed online procurement program fosters competitiveness for listed drugs.

WellNow Urgent Care No Longer Contracted with EmblemHealth in New York

Retrieved on: 
Friday, May 5, 2023

NEW YORK, May 5, 2023 /PRNewswire/ -- WellNow Urgent Care, one of the country's fastest-growing urgent care providers, announced that it will no longer be in network with EmblemHealth. Starting Saturday, May 6, this change will affect all WellNow Urgent Care clinics in the state of New York.

Key Points: 
  • NEW YORK, May 5, 2023 /PRNewswire/ -- WellNow Urgent Care , one of the country's fastest-growing urgent care providers, announced that it will no longer be in network with EmblemHealth.
  • Starting Saturday, May 6, this change will affect all WellNow Urgent Care clinics in the state of New York.
  • "WellNow Urgent Care clinics have worked tirelessly to provide convenient and essential care to our patients in the state of New York largely through extended hours," said John Radford, M.D., President at WellNow Urgent Care.
  • WellNow Urgent Care locations provide timely treatments for ailments, such as sprains, burns, lacerations, colds, flu and allergies, as well as on-site x-rays, lab testing and physicals.

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

Retrieved on: 
Wednesday, May 3, 2023

“These encouraging CD388 preclinical data provide further support for the potential of our Cloudbreak® DFC programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • “These encouraging CD388 preclinical data provide further support for the potential of our Cloudbreak® DFC programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • “CD388 has shown potential activity against seasonal and pandemic influenza strains, as well as activity against influenza strains resistant to neuraminidase inhibitors, the current standard of care.
  • The in vitro potency of CD388 translated into a high level of protection in mouse survival and quantitative lung burden treatment models.
  • Cidara is additionally advancing its first oncology DFC candidate, CD421, a first-in-class inhibitor of CD73, with an IND anticipated in 2024.

Molekule and Aura Expand in Global Education Market with Multiple Deployments and Orders

Retrieved on: 
Friday, April 28, 2023

Molekule and Aura technologies include the largest range of proprietary and patented, FDA-cleared air purification devices, which have been proven to destroy SARS-CoV-2, RSV, H1N1 flu virus, VOCs, allergens, mold and many other pollutants.

Key Points: 
  • Molekule and Aura technologies include the largest range of proprietary and patented, FDA-cleared air purification devices, which have been proven to destroy SARS-CoV-2, RSV, H1N1 flu virus, VOCs, allergens, mold and many other pollutants.
  • Globally, Aura is also expanding across several schools and districts in Israel and Hong Kong.
  • Jason DiBona, Chief Executive Officer of Molekule, noted, “Both Molekule and Aura provide an instantly deployable air quality and purification solution for the education sector, which includes software to enable users to assess and mitigate air quality across numerous devices.
  • Aura’s software capabilities enable centralized monitoring and remote management of installed units to ensure indoor air safety and quality.

CSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference

Retrieved on: 
Tuesday, April 25, 2023

MONTREAL, April 25, 2023 /CNW/ - CSL Seqirus, a global leader in influenza prevention, announced today the presentation of data from two Canadian studies at the 2023 Canadian Immunization Conference (CIC) in Ottawa, Ontario:

Key Points: 
  • MONTREAL, April 25, 2023 /CNW/ - CSL Seqirus, a global leader in influenza prevention, announced today the presentation of data from two Canadian studies at the 2023 Canadian Immunization Conference (CIC) in Ottawa, Ontario:
    A literature review of vaccine effectiveness of enhanced seasonal influenza vaccines in older adults; and
    A survey investigating pediatric influenza vaccination perceptions and uptake motivations and barriers.
  • Held from April 25-27, 2023, CIC brings together experts and thought-provoking speakers for a scientific program that engages and inspires future research, policies and practices.
  • "Every year, CIC is a key opportunity for leading experts to gather and discuss advancements in immunization," said Bertrand Roy, Country Head Medical Affairs, CSL Seqirus.
  • "This is especially important this year, as we debrief on key learnings from a very challenging flu season and align on ways to help prevent similar seasons moving forward."